Six years ago, Pfizer spun out a division of aging branded drugs, Mylan bolted on its generics empire, and the resulting company, Viatris, arrived on the tape in November 2020 promising a global footprint that would make it impossible to ignore. What followed was quieter and harder: a shrinking top line, a restructuring that touched nearly nine thousand jobs, and a sell-off of businesses worth roughly ten billion dollars in gross proceeds, from biosimilars to over-the-counter brands to women’s health. The company that remains is leaner, more focused, and, by one reading of the filed numbers, genuinely improving. The question is whether the stock’s recent climb has already priced in that improvement, or whether the math still has room the mood hasn’t caught.
“The math” is what the filed fundamentals justify on their own terms. “The mood” is what investors are currently paying. When those two readings diverge, that gap is usually where the story lives.
The story, briefly
Viatris’s revenue has fallen every year since 2021, yet its operating cash engine is quietly strengthening: adjusted gross margins improved meaningfully in the first half of 2026, and the company raised its full-year profit guidance after the first half. The stock has nearly doubled in a year, pushing the price-to-sales multiple well above its own historical median. The open question is whether the business’s improving profitability can grow fast enough to justify what the mood is now charging for it.
Five Years of Shrinking, One Year of Fixing
The revenue story is blunt. Full-year 2025 revenue came in at $14.3 billion, down from 2024, which was itself down from 2023. The company has shed a substantial slice of annual sales since its peak, a contraction about equal to what a mid-sized pharmaceutical company earns in a whole year. Most of that shrinkage was deliberate: Viatris sold off businesses it decided weren’t worth keeping, accepted the revenue hit, and bet that what remained would be more profitable per dollar.
That bet is showing early results. The Q2 2026 10-Q shows adjusted gross margins rising nearly a full percentage point from a year earlier. Think of gross margin as what’s left of each dollar of sales after paying for the drugs themselves, the factories, and the raw materials. Every point of improvement means the business keeps more of each sale before it pays for anything else. That’s not a dramatic swing, but it’s moving in the right direction, and it’s moving consistently.
Free cash flow for the quarter was $329 million, or closer to $449 million if restructuring costs are set aside. Annualized, that’s a business generating well over a billion dollars in cash each year, even while it’s still paying to reorganize itself. For a saver trying to understand what a company is actually worth, free cash flow is often more honest than reported earnings, because it counts real dollars in and out, not accounting adjustments.
The Debt Sitting in the Room
There is one number that earns its place at the table before anything else: long-term debt of $11.6 billion as of June 30, 2026. To feel the weight of that, consider that the whole company generates roughly four billion dollars in adjusted operating profit in a year. The debt pile is nearly three times that annual profit, which means, at current rates, it would take close to three years of every dollar of operating profit just to pay off the borrowings, with nothing left for anything else.
Viatris paid $241 million in interest in the first half of 2026 alone. That’s the cost of carrying the debt, and it’s why the company posted a net loss in Q2 even as the operating business was generating real cash. The interest bill eats the profit before it reaches the bottom line.
Management says the gross leverage ratio, total debt divided by adjusted operating profit, sits inside their stated target range. That’s a fair description of a company that has its debt under control but hasn’t yet paid it down to a level where it stops mattering. Anyone evaluating this business needs to hold that alongside the improving margins.
What the Mood Is Paying
Here is the contrast that earns its place at the top of any honest analysis: Viatris’s revenue has fallen for four consecutive years, yet the stock has gained 76% over the past twelve months, according to our data. The mood has run well ahead of the math.
Our data puts the current price-to-sales multiple, the price tag per dollar of annual revenue, at 1.4 times, against a decade median of 0.8 times. The stock is sitting at the ninetieth percentile of its own valuation history on that measure. That doesn’t mean it’s wrong, but it means the market is already pricing in a meaningful improvement, not just hoping for one.
GuruFocus, on September 16, 2026, flagged the stock as substantially overvalued against its proprietary estimate of intrinsic value, citing the elevated price-to-sales ratio relative to Viatris’s own history. Simply Wall St, as of September 19, 2026, lands on the opposite side, estimating fair value modestly above the current price. Both analyses are working from the same filed numbers and reaching different conclusions, which is an honest description of where the evidence sits right now.
Nine Wall Street analysts tracked by MarketBeat as of mid-September 2026 set a consensus implied level of roughly $18.70, with a high of $23 and a low of $13. Leerink initiated coverage on September 8, 2026, with a positive outlook and a $20 implied level. Barclays carries a positive outlook with a $22 implied level; Truist carries a positive outlook with a $20 implied level. The range from thirteen to twenty-three dollars is wide enough to tell you that even professionals with full access to the filings disagree substantially about what this business is worth.
Phase 2 and the Guidance Raise
What the bulls are buying is a story about what comes next. Viatris entered what management calls “Phase 2” in early 2026, pivoting toward ophthalmology, dermatology, and gastroenterology, categories where drugs are harder to copy and margins are wider. In September 2026, the company received Japanese regulatory approval for Wakix, a treatment for a sleep disorder, opening a new market for one of its newer assets.
After a strong first half, management raised full-year 2026 guidance to revenue between $14.55 billion and $14.95 billion, with adjusted earnings per share of $2.45 to $2.59. If the company lands at the midpoint of that earnings range and a buyer pays today’s price, the forward price-to-earnings multiple is genuinely low by pharmaceutical industry standards. The catch is that management also flagged meaningful second-half revenue headwinds from supply disruptions and slower growth in Greater China, so the midpoint is not guaranteed.
If earnings land at the filed-trend forecast and the business sustains something close to its current adjusted profit margins, a multiple in line with pharmaceutical peers would put the implied price meaningfully above today’s level. That is a conditional scenario, not a prediction, and it depends on the debt continuing to come down, the Phase 2 pipeline delivering, and the second-half headwinds not deepening. None of those conditions is certain.
Reading the numbers
- Q2 2026 total revenue: $3.8 billion. What it is: the cash Viatris collected from selling drugs in the quarter. What it means here: revenue grew 3.5% operationally year over year, the first meaningful growth in years. Everyday version: a shop that had been losing customers each quarter just posted its first quarter of more customers than the year before.
- Adjusted gross margin: 57.5%. What it is: of every dollar in drug sales, 57.5 cents remain after paying for production. What it means here: margins are rising, meaning the remaining business is more profitable per sale than the old, larger one. Everyday version: a restaurant that used to keep 56 cents of every dollar after food costs now keeps nearly 58 cents, a small shift that compounds across billions in sales.
- Free cash flow, Q2 2026: $329 million. What it is: actual cash generated after capital spending, the number that shows whether the business can fund itself. What it means here: even with heavy interest payments, the company is producing real cash each quarter. Everyday version: a household earning $5,000 a month, paying $1,500 in debt service, and still banking $1,000 after all other bills.
- Long-term debt: $11.6 billion. What it is: money borrowed and not yet repaid. What it means here: at roughly 2.9 times annual operating profit, the debt is manageable but not small. Everyday version: a family earning $40,000 a year carrying $116,000 in mortgage debt, inside normal bounds but leaving little room for surprises.
- Forward P/E: approximately 6.7 times. What it is: the price tag per dollar of expected annual profit. What it means here: low by pharmaceutical industry standards, which is why analysts are divided between “cheap” and “cheap for a reason.” Everyday version: paying $6.70 for a business that earns $1 a year, versus a typical peer that might cost $12 to $15 for the same dollar of earnings.
For the standing yardsticks on Viatris: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Viatris.
Sources
- Viatris 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Viatris 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Viatris Q2 2026 earnings press release (PR Newswire)
- Viatris Q2 2026 earnings call transcript (The Motley Fool)
- GuruFocus: VTRS valuation analysis, September 16, 2026
- Simply Wall St: Viatris fair value and Wakix approval, September 19, 2026
- MarketBeat: VTRS analyst consensus and price targets
- Finterra: Viatris Phase 2 strategy, February 26, 2026
- Seeking Alpha: Viatris cash generation and re-rating analysis
